SWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma

Potent in vitro and in vivo antitumor activity of sorafenib against human intrahepatic cholangiocarcinoma cells

(2011) Hiroaki Sugiyama et al.   JOURNAL OF GASTROENTEROLOGY

Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer

(2010) Juan Valle et al.   NEW ENGLAND JOURNAL OF MEDICINE

Intra-hepatic and extra-hepatic cholangiocarcinoma: New insight into epidemiology and risk factors

(2010) Vincenzo Cardinale   World Journal of Gastrointestinal Oncology

Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial

(2009) C Bengala et al.   BRITISH JOURNAL OF CANCER

Sorafenib inhibits signal transducer and activator of transcription-3 signaling in cholangiocarcinoma cells by activating the phosphatase shatterproof 2

(2009) Boris R. A. Blechacz et al.   HEPATOLOGY

Capecitabine plus oxaliplatin as first-line treatment in patients with advanced biliary system adenocarcinoma: a prospective multicentre phase II trial

(2008) O Nehls et al.   BRITISH JOURNAL OF CANCER

Sorafenib in Advanced Hepatocellular Carcinoma

(2008) Josep M. Llovet et al.   NEW ENGLAND JOURNAL OF MEDICINE

Systemic Therapy for Biliary Tract Cancers

(2008) A. F. Hezel et al.   ONCOLOGIST